Currently out of the existing stock ratings of Cory Kasimov, 33 are a HOLD (30.56%), 71 are a BUY (65.74%), 4 are a SELL (3.7%).

Cory Kasimov

Work Performance Price Targets & Ratings Chart

Analyst Cory Kasimov, currently employed at EVERCORE, carries an average stock price target met ratio of 64.63% that have a potential upside of 28.79% achieved within 302 days. Previously, Cory Kasimov worked at JPMORGAN.

Cory Kasimov’s has documented 237 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BNTX, BioNTech SE at 19-Nov-2024.

Wall Street Analyst Cory Kasimov

Analyst best performing recommendations are on EDIT (EDITAS MEDICINE).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.

Average potential price target upside

of $62.54 (23.5%) on BIIB (BIOGEN).
of $47.18 (22.14%) on MRNA (MODERNA).
of $41.89 (113.66%) on BLUE (BLUEBIRD BIO).

ACAD ACADIA Pharmaceuticals ALKS Alkermes Plc BLUE Bluebird bio BMRN Biomarin Pharmaceutical BNTX BioNTech SE CLVS Clovis Oncology GILD Gilead Sciences INCY yte MRNA Moderna NVCR Novocure Ltd PBYI Puma Biotechnology RARE Ultragenyx SANA Sana Biotechnology VRTX Vertex Pharmaceuticals SAGE Sage Therapeutic AMGN Amgen CERE Cerevel Therapeutics Holdings EDIT Editas Medicine GBT Global Blood Therapeutics KRTX Karuna Therapeutics REGN Regeneron Pharmaceuticals BIIB Biogen CELG Celgene JNCE Jounce Therapeutics LEGN Legend Biotech Corp

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Andrew Fein (HC WAINWRIGHT)